Skip to main content
Abliva logo

Abliva — Investor Relations & Filings

Ticker · ABLI ISIN · SE0002575340 LEI · 5493005YV22OTMUHZ183 ST Manufacturing
Open in API
Filings indexed 594 across all filing types
Latest filing 2016-04-26 Share Issue/Capital Cha…
Country SE Sweden
Listing ST ABLI

About Abliva

https://abliva.com

Abliva is a biopharmaceutical company that discovers and develops medicines for the treatment of primary mitochondrial diseases. These are rare, congenital, and often severe genetic disorders that occur when the cell's energy converters, the mitochondria, are dysfunctional. The company's research and development is focused on creating novel therapies aimed at restoring mitochondrial function and addressing the significant unmet medical needs of patients. Abliva's primary goal is to deliver treatments that provide meaningful clinical benefits for individuals suffering from these debilitating conditions.

Recent filings

Filing Released Lang Actions
NeuroVive insiders and employees intend to subscribe for a minimum of 5.4 million SEK
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated April 26, 2016, announcing that insiders and employees intend to subscribe to a preferential rights issue. The text details the terms of the new share issue, including subscription price, number of shares/warrants per unit, and expected capital raise (SEK 94.4 million). This content directly relates to fundraising, financing activities, and changes in the capital structure. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). It is not an official regulatory form like 10-K, nor is it a general earnings release (ER) or a report publication announcement (RPA), as it is the primary announcement of the financing event itself.
2016-04-26 English
NeuroVive: storägare avser deltaga i företrädesemissionen
Capital/Financing Update Classification · 1% confidence The document is a press release dated April 18, 2016, announcing that a major shareholder (Baulos Capital Belgium SA) intends to participate in an upcoming rights issue (företrädesemission) for NeuroVive Pharmaceutical AB. The text explicitly discusses subscription commitments, subscription periods, and the involvement of management in subscribing to the offering. This content directly relates to fundraising, financing activities, and changes in capital structure. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). The document length is relatively short (2436 chars), but its primary function is to announce a specific financing event, not just the publication of a report.
2016-04-18 Swedish
NeuroVive: large shareholder to participate in the rights issue
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing that a major shareholder (Baulos Capital Belgium SA) intends to participate in an upcoming rights issue, and that management also desires to subscribe. It details the subscription period and commitment amount. A rights issue is a form of capital fundraising or capital structure change. This aligns directly with the definition for 'Capital/Financing Update' (CAP). It is not an earnings release (ER), an annual report (10-K), or a general regulatory filing (RNS), as it concerns a specific financing event.
2016-04-18 English
NeuroVive offentliggör publicering av prospekt och meddelar om ändrat datum för publicering av kvartalsrapport 1, 2016
Capital/Financing Update Classification · 1% confidence The document is explicitly titled "Pressmeddelande" (Press Release) and is dated April 14, 2016. The primary content announces two key actions: 1) The publication of a prospectus ('offentliggör publicering av prospekt') related to a rights issue (nyemission), and 2) A change in the publication date for the Q1 2016 interim report ('ändrat datum för publicering av kvartalsrapport 1, 2016'). Since the document's main function is to announce the availability of a prospectus (a financing/capital activity document) and to announce a change regarding a future report, it is not the full report itself (like 10-K or IR). The announcement of a prospectus related to a rights issue strongly points towards a Capital/Financing Update (CAP). While it mentions the Q1 report date change, the focus on the prospectus and the associated fundraising details makes CAP the most specific fit over a general Report Publication Announcement (RPA) or Regulatory Filing (RNS). The document length (6549 chars) is substantial, but its nature is purely informational announcement rather than the detailed financial filing itself.
2016-04-14 Swedish
NeuroVive publishes prospectus and announces new publication date of the Q1 interim report
Report Publication Announcement Classification · 1% confidence The document is explicitly titled "NEWS RELEASE" and announces two main things: the publication of a prospectus related to a new share issue and warrants, and the postponement of the Q1 interim report publication date. The core action described is the announcement of the prospectus availability and the scheduling change for another report. This fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing, release, or publication of company reports, especially when the document itself is a press release announcing the availability of a formal document (the prospectus) and rescheduling another report (the Q1 interim report). While it mentions the Q1 interim report (which would be an 'IR'), the document's primary function here is announcing the publication/schedule change, making RPA the most accurate classification based on the 'MENU VS MEAL' rule.
2016-04-14 English
NeuroVive förstärker organisationen med Cecilia Hofvander som ansvarig för IR och kommunikation
Board/Management Information Classification · 1% confidence The document is explicitly titled "PRESSMEDDELANDE" (Press Release) and announces the recruitment of a new Investor Relations and Communications Director, Cecilia Hofvander. This type of announcement concerns changes in senior management/personnel responsible for investor communication. Based on the provided definitions, the most fitting category is 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management. Although it relates to IR, it is a personnel change announcement, not a standard financial report or investor presentation.
2016-04-11 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.